The interaction between statins and exercise: Mechanisms and strategies to counter the musculoskeletal side effects of this combination therapy

Ochsner Journal

Volumn 15, Issue 4, 2015, Pages 429-437

  Deichmann, R E ^a,b   Lavie, Carl J ^b,c   Asher, Timothy ^b   DiNicolantonio, James J ^d   O’Keefe, James H ^d   Thompson, Paul D ^e  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^d Saint Luke's Health System Missouri   (United States)

^e HARTFORD HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Exercise; Hydroxymethylglutaryl CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; CARNITINE; CERIVASTATIN; CREATINE KINASE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UBIDECARENONE; VITAMIN D;

CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENZYME DEFICIENCY; ENZYME INDUCTION; ENZYME INHIBITION; EXERCISE; FATIGUE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; JOINT DISLOCATION; JOINT SPRAIN; META ANALYSIS (TOPIC); MUSCLE FATIGUE; MUSCLE INJURY; MUSCLE STRAIN; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; NONHUMAN; PHYSICAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SIMVASTATIN ASSOCIATED MYALGIA; SPRAIN; THERAPY EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84949191337     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Joyner MJ, Green DJ. Exercise protects the cardiovascular system: effects beyond traditional risk factors. J Physiol. 2009 Dec 1;587(Pt 23):5551-5558. doi: 10.1113/jphysiol.2009.179432.
2. SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-799. doi: 10.1056/NEJMoa0801936.
3. Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012 Nov;40(4):88-95. doi: 10.3810/psm.2012.11.1991.
4. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin- induced mitochondrial dysfunction. Ochsner J. 2010 Spring;10(1): 16-21.
5. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13; 376(9753):1670-1681. doi: 10.1016/S0140-6736(10)61350-5.
6. Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006 Apr 17;97(8A):69C-76C.
7. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997 Oct;46(10):1206-1210.
8. Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012 Jan 15;109(2):282-287. doi: 10.1016/j.amjcard.2011.08.045.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17; 106(25):3143-3421.
10. Eckel RH, Jakicic JM, Ard JD, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S76-S99. doi: 10.1161/01.cir.0000437740.48606.d1. Errata in: Circulation. 2015 Jan 27;131(4):e326. Circulation. 2014 Jun 24;129(25 Suppl 2): S100-S101.
11. Centers for Disease Control and Prevention. Health, United States, 2011. http://www.cdc.gov/nchs/data/hus/hus11.pdf. Accessed June 15, 2015.
12. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012-1022.
13. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibitionof HMG-CoA reductase. Science. 2001 May 11;292(5519): 1160-1164.
14. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007 Jun 12;49(23):2231-2237.
15. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6): 889-892.
16. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993 Mar;33(3): 226-229.
17. Rosenson RS. Current overview of statin-induced myopathy. Am JMed. 2004 Mar 15;116(6):408-416.
18. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A,Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010 Mar 1;33(3):171-187. doi: 10.2165/11319380-000000000-00000.
19. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005 Feb;59(2):239-252.
20. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998 Aug;46(2):101-110.
21. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol. 2006 Sep 1;98(5):705-706.
22. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 2001 Dec;70(6):546-551.
23. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010 Jun;210(2):337-343. doi: 10.1016/j.atherosclerosis.2009.11.033.
24. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-S71. doi: 10.1016/j.jacl.2014.03.004.
25. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006 Sep;210(1):94-102.
26. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29(8):703-712.
27. Banach M, Serban C, Sahebkar A, et al; Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015 Jan;90(1):24-34. doi: 10.1016/ j.mayocp.2014.08.021.
28. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015 Feb;238(2):329-335. doi: 10.1016/j. atherosclerosis.2014.12.016.
29. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011 Mar;215(1):23-29. doi: 10. 1016/j.atherosclerosis.2010.11.039.
30. Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 2002 May;9(5):493-504.
31. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2560-2566.
32. Phillips C, Owens D, Collins P, Tomkin GH. Low density lipoprotein non-esterified fatty acids and lipoprotein lipase in diabetes. Atherosclerosis. 2005 Jul;181(1):109-114.
33. P äivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005 Jul;78(1):60-68.
34. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010 Oct;42(4):469-479. doi: 10.1002/mus.21817.
35. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann
36. Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci. 1995 Nov;50 Spec No:11-16.
37. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 1;99(3):410-414.
38. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther. 2005 Feb;30(1):21-37.
39. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2):153-162.
40. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 Jan;87(1):130-133. doi: 10.1038/clpt.2009.197.
41. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B15 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609-1616. doi: 10.1016/j.jacc.2009.04. 053.
42. Zeviani M, Carelli V. Mitochondrial disorders. Curr Opin Neurol. 2007 Oct;20(5):564-571.
43. Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007 Mar; 117(3):765-772.
44. Salviati L, Trevisson E, Rodriguez Hernandez MA, et al. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. J Med Genet. 2012 Mar;49(3):187-191. doi: 10.1136/jmedgenet-2011-100394.
45. L ópez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006 Dec;79(6):1125-1129.
46. Ruaño G, Windemuth A, Wu AH, et al. Mechanisms of statin induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011 Oct;218(2):451-456. doi: 10.1016/j. atherosclerosis.2011.07.007.
47. Lavie CJ, Dinicolantonio JJ, Milani RV, O’Keefe JH. Vitamin D and cardiovascular health. Circulation. 2013 Nov 26;128(22):2404-2406. doi: 10.1161/CIRCULATIONAHA.113.002902.
48. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency—a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf). 2009 Jul;71(1):154-155. doi: 10.1111/j.1365-2265.2008.03448.x.
49. Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002 Aug 31;360(9334):717.
50. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004 Dec 14;63(11):2188.
51. Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle’s disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004 Jul;41(Pt 4):338-340.
52. Dupuis L, Oudart H, Ren é F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004 Jul 27;101(30): 11159-11164.
53. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96-103. doi: 10. 1161/CIRCULATIONAHA.112.136101.
54. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012 Oct;40(4):188-194.
55. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004 Dec 1;292(21):2585-2590.
56. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010 Jun;30(6):541-553. doi: 10.1592/phco.30.6.541.
57. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012 Aug 13;172(15):1180-1182. doi: 10.1001/archinternmed.2012.2171.
58. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013 Jul 22;173(14):1-10 doi: 10.1001/jamainternmed.2013.6184.
59. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010 Aug;21(4):324-328. doi: 10.1097/MOL.0b013e32833c1edf.
60. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009 Sep; 102(9):625-633. doi: 10.1093/qjmed/hcp093.
61. Swift DL, Lavie CJ, Johannsen NM, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J. 2013;77(2):281-292.
62. Vuori IM, Lavie CJ, Blair SN. Physical activity promotion in the health care system. Mayo Clin Proc. 2013 Dec;88(12):1446-1461. doi: 10.1016/j.mayocp.2013.08.020.
63. Blair SN, Morris JN. Healthy hearts—and the universal benefits of being physically active: physical activity and health. Ann Epidemiol. 2009 Apr;19(4):253-256. doi: 10.1016/j.annepidem.2009.01.019.
64. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;1:CD004816. doi: 10.1002/14651858.CD004816.pub5.
65. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-590. doi: 10.1016/S0140-6736(12)60367-5.
66. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013 Feb 2; 381(9864):394-399. doi: 10.1016/S0140-6736(12)61426-3.
67. Green DJ, O’Driscoll G, Joyner MJ, Cable NT. Exercise and cardiovascular risk reduction: time to update the rationale for exercise? J Appl Physiol (1985). 2008 Aug;105(2):766-768. doi: 10.1152/japplphysiol.01028.2007.
68. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21): 2195-2207. doi: 10.1056/NEJMoa0807646.
69. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation. 1996 Aug 15;94(4):690-697.
70. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol. 2002 Feb 20;39(4):683-688.
71. Bruckert E, Hayem G, Dejager S, Yau C, B égaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-414.
72. O’Keefe JH, Patil HR, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. 2012 Jun;87(6):587-595. doi: 10.1016/j.mayocp.2012.04.005.
73. O’Keefe JH, Schnohr P, Lavie CJ. The dose of running that best confers longevity. Heart. 2013 Apr;99(8):588-590. doi: 10.1136/heartjnl-2013-303683.
74. O’Keefe JH, Lavie CJ. Run for your life at a comfortable speed and not too far. Heart. 2013 Apr;99(8):516-519. doi: 10.1136/heartjnl-2012-302886.
75. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 1995 Oct;27(10):2397-2402.
76. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998 Jan;19(1):26-37.
77. Reijneveld JC, Koot RW, Bredman JJ, Joles JA, Bär PR. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res. 1996 Jun;39(6):1028-1035.
78. Nakahara K, Kuriyama M, Sonoda Y, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol. 1998 Sep;152(1):99-106.
79. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995 Mar;131(1):163-174.
80. Joy T, Hegele RA. Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients. Can J Cardiol. 2009 Aug; 25(8):453.
81. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2;158(7):526-534. doi: 10.7326/0003-4819-158-7-201304020- 00004.
82. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007 Nov 1;100(9):1400-1403.
83. Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin- treated mice and increases exercise endurance. J Appl Physiol (1985).2012 Aug;113(3):479-486. doi: 10.1152/japplphysiol.01362.2011.
84. Mizuno K, Tanaka M, Nozaki S, et al. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition. 2008 Apr;24(4): 293-299. doi: 10.1016/j.nut.2007.12.007. Erratum in: Nutrition. 2008 Jun;24(6):616.
85. Ylikoski T, Piirainen J, Hanninen O, Penttinen J. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Mol Aspects Med. 1997;18 Suppl:S283-S290.
86. Kon M, Tanabe K, Akimoto T, et al. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr. 2008 Oct;100(4):903-909. doi: 10.1017/ S0007114508926544.
87. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007 May 15;99(10):1409-1412.
88. Hassani A, Horvath R, Chinnery PF. Mitochondrial myopathies: developments in treatment. Curr Opin Neurol. 2010 Oct;23(5): 459-465. doi: 10.1097/WCO.0b013e32833d1096.
89. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve. 2010 Nov;42(5):739-748. doi: 10.1002/mus. 21758.
90. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005 Nov;62(11): 1709-1712.
91. Cooke M, Iosia M, Buford T, et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. 2008 Mar 4;5:8. doi: 10.1186/1550-2783-5-8.
92. Kon M, Kimura F, Akimoto T, et al. Effect of coenzyme Q10 supplementation on exercise-induced muscular injury of rats. Exerc Immunol Rev. 2007;13:76-88.
93. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol. 2012 Aug 15;110(4):526-529. doi: 10.1016/j.amjcard.2012.04.026.
94. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1-4):91-100.
95. Mas E, Mori TA. Coenzyme Q(10) and statin myalgia: what is the evidence? Curr Atheroscler Rep. 2010 Nov;12(6):407-413. doi: 10.1007/s11883-010-0134-3.
96. Bhuiyan J, Seccombe DW. The effects of 3-hydroxy-3- methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids. 1996 Aug;31(8):867-870.
97. Arduini A, Peschechera A, Giannessi F, Carminati P. Improvement of statin-associated myotoxicity by L-carnitine. J Thromb Haemost. 2004 Dec;2(12):2270-2271.
98. DiNicolantonio JJ. CoQ10 and L-carnitine for statin myalgia? Expert Rev Cardiovasc Ther. 2012 Oct;10(10):1329-1333. doi: 10.1586/erc.12.92.
99. Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010 Jul;103(7):690-692. doi: 10.1097/SMJ.0b013e3181e21088.
100. Backes JM, Barnes BJ, Ruisinger JF, Moriarty PM. A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. Atherosclerosis. 2011 Sep;218(1):247-249. doi: 10.1016/j.atherosclerosis.2011.04.037.
101. Kurnik D, Hochman I, Vesterman-Landes J, et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf). 2012 Jul;77(1):36-41. doi: 10.1111/j.1365-2265.2011.04321.x.